Rosuvastatin promotes the improvement of nephrogenic markers in obstructive nephropathy model

LUCIANA MAZZEI; ISABEL MERCEDES GARCÍA; NEIL G. DOCHERTY; WALTER MANUCHA

San Juan

Congreso; 2 reunión Conjunta Sociedades de Biología República Argentina; 2011

Sociedades de Biología de la República Argentina

Congenital obstructive nephropathy is characterized by tubular apoptosis and fibrosis. Statins prevent apoptotic and fibrotic processes in renal cells. The present study examined whether rosuvastatin (Ros) could protect against neonatal obstructive nephropathy in the rat in association with the preservation of the expression of markers of nephrogenesis. Methods: Neonatal rats (n=5) underwent unilateral ureteral obstruction (UUO) or sham surgery (control), were randomized to receive oral Ros (10mg/kg/day) or vehicle for 2 weeks. Renal tissue was processed for quantification of tubular dilatation, apoptosis, fibrosis, TNF-a, TGF-b1, WT1, Snail, BMP-7 and E-cadherin protein expression. Results: UUO significantly increased tubular apoptosis, dilatation and tubule-interstitial fibrosis coupled to increases in TNF-a and TGF-b1 mRNA expression. Ros-treat during UUO markedly protected against these changes. Preservation of renal WT1, Snail, BMP-7 and E-cadherin, was also associated to Ros treatment. Conclusions: The protective effects of Ros were sufficient to preserve a normal profile of expression for a number of markers of nephrogenesis suggesting that renal development is likely to continue despite of obstruction.